About Allogene
Allogene is a company based in San Francisco (United States) founded in 2018 by David Chang and Arie Belldegrun. It operates as a HealthTech. Allogene has raised $531.77 million across 5 funding rounds from investors including Fidelity Investments, Pfizer and TPG. The company has 229 employees as of December 31, 2024. Allogene offers products and services including AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329. Allogene operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
- Employees 229 as on 31 Dec, 2024
- Founders David Chang, Arie Belldegrun
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Allogene Therapeutics, Inc.
-
Annual Revenue
$22 K-76.84as on Dec 31, 2024
-
Net Profit
$-257.59 M21.29as on Dec 31, 2024
-
EBITDA
$-243.84 M18.8as on Dec 31, 2024
-
Total Equity Funding
$531.77 M (USD)
in 5 rounds
-
Latest Funding Round
$15 M (USD), Grant
Apr 26, 2024
-
Investors
Fidelity Investments
& 11 more
-
Employee Count
229
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Allogene
Allogene is a publicly listed company on the NASDAQ with ticker symbol ALLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Allogene
Allogene offers a comprehensive portfolio of products and services, including AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Innovative allogeneic CAR T therapy is developed for patients.
Frontline treatment for large B-cell lymphoma is provided.
Therapy for advanced renal cell carcinoma is offered.
Treatment for autoimmune diseases is being developed now.
Unlock access to complete
Unlock access to complete
Leadership Team
40 people
Software Development Team
16 people
Product Management Team
10 people
Scientific Team
10 people
Board Team
8 people
Operations Team
8 people
Senior Team
5 people
Scientist Team
4 people
Unlock access to complete
Funding Insights of Allogene
Allogene has successfully raised a total of $531.77M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $15 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $15.0M
-
First Round
First Round
(01 Feb 2016)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Grant - Allogene | Valuation |
investors |
|
| Sep, 2018 | Amount | Series A - Allogene | Valuation | Perceptive Advisors , Deerfield | |
| Jun, 2018 | Amount | Grant - Allogene | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Allogene
Allogene has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Pfizer and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Biomedical innovations are transformed into therapies by Vida Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Allogene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Allogene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Allogene Comparisons
Competitors of Allogene
Allogene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Allogene
Frequently Asked Questions about Allogene
When was Allogene founded?
Allogene was founded in 2018.
Where is Allogene located?
Allogene is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Allogene?
David Chang is the current CEO of Allogene. They have also founded this company.
Is Allogene a funded company?
Allogene is a funded company, having raised a total of $531.77M across 5 funding rounds to date. The company's 1st funding round was a Grant of $58.34K, raised on Feb 01, 2016.
How many employees does Allogene have?
As of Dec 31, 2024, the latest employee count at Allogene is 229.
What is the annual revenue of Allogene?
Annual revenue of Allogene is $22K as on Dec 31, 2024.
What does Allogene do?
Allogene Therapeutics is engaged in the development of allogeneic CAR T cell therapies targeting blood cancers, solid tumors, and autoimmune diseases. The company is recognized for its innovative AlloCAR T platform, which enables scalable manufacturing and on-demand treatment availability. Research and clinical trials, such as ALPHA3 and RESOLUTION, are conducted to address large B-cell lymphoma and autoimmune conditions. Multiplex gene-engineering and proprietary lymphodepletion technologies are utilized to optimize product efficacy. Partnerships and strategic collaborations are maintained to expand development activities globally.
Who are the top competitors of Allogene?
Allogene's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Allogene offer?
Allogene offers AlloCAR T™, Cemacabtagene Ansegedleucel (Cema-Cel), ALLO-316, and ALLO-329.
Is Allogene publicly traded?
Yes, Allogene is publicly traded on NASDAQ under the ticker symbol ALLO.
Who are Allogene's investors?
Allogene has 12 investors. Key investors include Fidelity Investments, Pfizer, TPG, Citadel, and European Union.
What is Allogene's ticker symbol?
The ticker symbol of Allogene is ALLO on NASDAQ.